In Challenging Opioid Market, Acura Still Seeks A Partner
This article was originally published in The Pink Sheet Daily
Executive Summary
Acura will meet with FDA Dec. 5 to review results of a Phase II study evaluating the nasal abuse potential of its hydrocodone/acetaminophen combination product, made with its Aversion technology. On the OTC side, distribution for its tamper-resistant decongestant Nexafed has picked up momentum.